Following the announcement of a significant growth strategy, ImmunityBio, Inc. (NASDAQ: IBRX) has experienced a notable increase in its stock value. As of the latest session, IBRX shares have risen by 11.56%, reaching $6.95.
Initiation Of ANKTIVA Therapy In The US
ImmunityBio (IBRX) has initiated the treatment of multiple patients in the United States with ANKTIVA, its recently approved immunotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. The U.S. Food and Drug Administration (FDA) granted approval for ANKTIVA on April 22, 2024, for treating patients with BCG-unresponsive NMIBC CIS, both with and without papillary tumors.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ANKTIVA, an IL-15 agonist, is administered intravesically in combination with BCG. This treatment marks the first FDA-approved immunotherapy for NMIBC that enhances the body’s NK and killer T-cell immune response to target tumor cells, while also activating memory T cells. This dual activation has led to a sustained complete response in some patients for over 47 months.
Widespread Adoption And Administration
ImmunityBio is set to provide this pioneering immunotherapy to eligible bladder cancer patients less than two months post-FDA approval. There has been substantial interest from urologists treating NMIBC, signifying a new era in immunotherapy that extends beyond checkpoint inhibitors to cytokine-based treatments.
The initial recipients of commercial doses are distributed across the U.S., with many being treated by community urologists. ANKTIVA’s administration does not require specialized handling or equipment, facilitating its use in standard medical practices.
ANKTIVA’s unique action mechanism allows urologists to administer it in their offices and clinics, thus enabling a broader patient reach within familiar settings. This advancement promises to extend the benefits of ImmunityBio’s science to an increasing number of eligible NMIBC patients.
In a related development, ImmunityBio announced in May that it had sufficient drug substance for 170,000 doses of ANKTIVA, ensuring ample supply for both commercial distribution and clinical trials.
